This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
Reminder - Five CTS Forms will be updated on Monday September 2, 2019. Some of the forms are posted ...